IP Library Granted Patent US 11,045,490
Granted Patent B2
US 11,045,490 · App. 16/856,029 · Granted Jun 29, 2021

Injectable monophase hydrogels

Inventor: Pierre F. Lebreton (Annecy, FR)
Assignee: ALLERGAN INDUSTRIE, SAS
A61K31/738A61K9/0019A61L27/20A61L27/50A61L27/52C08B37/0072C08J3/24C08L5/08C08J2305/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,045,490
App. No.
16/856,029
Granted
Jun 29, 2021
Kind
B2
Abstract

An injectable monophase hydrogel is provided that is made of a reaction mixture of hyaluronic acids having different molecular weights.

Claims (9)

1. An injectable hydrogel useful in preventing tissue adhesion, the hydrogel made by a process comprising the steps of: 1) forming a mixture of a first hyaluronic acid salt product having a first molecular weight and a second hyaluronic acid salt product having a second molecular weight greater than the first molecular weight, wherein the first hyaluronic acid salt product and the second hyaluronic acid salt product are two separate pre-existing products prior to the forming step, wherein the mixture contains about 90% by weight of the first hyaluronic acid salt product and about 10% by weight of the second hyaluronic acid salt product, wherein the first hyaluronic acid salt product is a sodium salt having a molecular weight of about 3×10 5 Da, and the second hyaluronic acid salt product is a sodium salt having a molecular weight of about 3×10 6 Da; 2) cross-linking the mixture of step 1 ) in an aqueous solvent in the presence of an effective and non-excessive amount of at least one cross-linking agent, such that the degree of cross-linking, defined by the ratio: 100×(total number of reactive groups in said cross-linking agent/total number of disaccharide units in the first hyaluronic acid salt and second hyaluronic acid salt), is theoretically between 0.5 and 70%; and 3) formulating the cross-linked mixture of step 2 ), into a solution buffered to a pH of between 6.5 and 7.5.

2. The hydrogel according to claim 1 , wherein said mixture has an intrinsic viscosity of less than 1900 ml/g.

3. The hydrogel according of claim 1 , wherein said cross-linking agent is selected from bifunctional crosslinking agents and mixtures thereof.

4. The hydrogel according to claim 1 , wherein the degree of cross-linking is theoretically between 4 and 50%.

5. The hydrogel according to claim 1 , wherein said cross-linking agent is selected from epichlorohydrin, divinyl sulfone, 1,4-bis(2,3-epoxypropoxy)butane, 1,2-bis(2,3-epoxypropoxy)ethylene, 1-(2,3-epoxypropyl)-2,3-epoxycyclohexane, aldehydes, and mixtures thereof.

6. The hydrogel according to claim 5 , wherein said aldehydes are selected from formaldehyde, glutaraldehyde, crotonaldehyde, and mixtures thereof.

7. The hydrogel according to claim 1 , wherein said cross-linking agent is 1,4-bis(2,3-epoxypropoxy)butane.

8. The hydrogel according to claim 1 , wherein the pH is between 7 and 7.4.

9. The hydrogel according to claim 1 , wherein the pH is between 7.1 and 7.3.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 11, 2021
From: LEBRETON, PIERRE
To: CORNEAL INDUSTRIE
Reel/Frame 055884/0420 →
CHANGE OF NAME Recorded Apr 11, 2021
From: CORNEAL INDUSTRIE
To: ALLERGAN INDUSTRIE, SAS
Reel/Frame 055884/0426 →
Priority Claims (1)
FR 030444 · Apr 10, 2003 · national
Continuity (8)
Continuation 16137447 · Sep 20, 2018
Continuation 15209561 · Jul 13, 2016
Continuation 14535220 · Nov 6, 2014
Continuation 14024916 · Sep 12, 2013
Continuation 13566767 · Aug 3, 2012
Continuation 12782488 · May 18, 2010
Division 10552309
Related Publication 20200246375A1 · Aug 6, 2020